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The clerodane diterpenoid salvinorin A (1), the main active component of the psychotropic herb
Salvia divinorum, has been reported to be a potent agonist at the k-opioid receptor. Computer modeling
suggested that splendidin (2) from S. splendens, as well as related compounds, might possess similar
activities. In the present study, this hypothesis was tested by determination of the binding properties of a
series of structural congeners, compounds 2–8, at the m-, d-, and k-opioid receptors. However, none of
these compounds showed significant binding to any of the opioid-receptor subtypes, thus disproving the
above hypothesis.
The novel compounds 7 and 8 were obtained semi-synthetically by selective modification of
salvifarin (5), isolated from Salvia farinacea, upon epoxide-ring opening with AcOH in the presence of
indium(III) triflate. Also, the X-ray crystal structure of salvifaricin (6 ; Fig.), obtained from S. farinacea,
was determined for the first time and used, in combination with in-depth NMR experiments, to elucidate
the absolute configurations of the new products. Our experiments demonstrate that the relatively well-
accessible diterpenoid 6 could be used as starting material for future studies into the structure–activity
relationship at the k-opioid receptor.
Introduction. – Salvia divinorum, also referred to as <magic mint= or <holy mint=, is a
psychotropic plant first described in the 1960s [1]. A number of clerodane diterpenoids
have been isolated from this species [2], of which salvinorin A (1) was identified as the
major active constituent [3] [4]. This compound was subsequently shown to act as an
agonist at the k-opioid receptor, the first non-nitrogenous compound to do so [5] [6].
Modeling studies with 1 led to the hypothesis that splendidin (2), another clerodane
diterpenoid from Salvia splendens, might also possess k-opioid activity [5]. However,
the study of structure–activity relationships (SAR) by a number of groups using
modified derivatives of 1 have shown particular structural requirements lacking in 2,
including an acetyl (Ac) group or another small substituent at the C(2) atom [7], as well
as trans-fused B/C rings, with a b-orientated H-atom at C(8) [8].
The purpose of the present study was to test whether or not splendidin (2) is,
indeed, a k-opioid agonist, and to compare its biological properties with those of other
diterpenoids from S. splendens, including salviarin (3) and splenolide B (4). We also
isolated the clerodanes salvifarin (5) and salvifaricin (6) from S. farinacea, and tested
them together with the semi-synthetic derivatives 7 and 8.
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Results and Discussion. – 1. X-Ray Crystal Structure of 6. The known compounds
2–6 were isolated from the corresponding natural sources, and identified by
comparison of their spectroscopic data with those published previously. The X-ray
crystal structures of 1 [3], 3 [9], and 5 [10] have been published before, and a single-
crystal X-ray diffraction analysis of salvifaricin (6) was carried out in this study
(Figure), which confirmed that the configuration of 6 is the same as in salvifarin (5).
Figure. X-Ray crystal structure of salvifaricin (6). Arbitrary atom numbering (different from diterpenoid
numbering). Ellipsoids are represented at the 30% probability level, and H-Atoms are omitted for
clarity.
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2. Epoxide-Ring Opening of 5 and Structural Analysis of the Resulting Congeners.
Starting from salvifarin (5), we synthesized the two new compounds 7 and 8 by Lewis
acid-catalyzed epoxide-ring opening with AcOH. As Lewis acid, indium trifluorome-
thanesulfonate (indium triflate) was chosen because of the previously reported
effectiveness of InIII in promoting the selective ring opening of epoxides and its wide
tolerance to other functional groups [11]. The resulting two geometric isomers, 7 and 8,
were characterized by MS and NMR, and their structures were confirmed by
comparison of their 13C- and 1H-NMR data with those of 5 (Tables 1 and 2, resp.).
A critical element in the discrimination of the two regioisomers 7 and 8 was the
accurate 1H- and 13C-NMR assignment of HC(1) and HC(2). In the parent
compound 5, the two a-H-atoms at these positions resonate as an unresolved multiplet
at d(H) 3.54, showing HMQC correlations with the respective C-atom signals at d(C)
58.7 and 46.2. HMBC Experiments showed a correlation between the signal at d(C)
46.2 and d(H) 7.01 (HC(3)). Thus, the signal at d(C) 46.2 was assigned to C(2).
HMBC also showed a correlation between d(C) 58.7 and d(H) 2.07 (HC(10)); thus,
this signal was assigned to C(1).
High-resolution CI-MS analysis of the quasi-molecular [MþNH4]þ ion of 7
indicated the molecular formula C22H24O8, which confirmed the addition of AcOH to 5.
The 13C-NMR spectrum of 7 (Table 1) was very similar to that of 5, except for
additional peaks for an AcO moiety at d(H) 21.0 (Me) and 170.2 (C¼O). At the same
time, the signals for C(1) and C(2) were shifted to d(C) 70.6 and 71.4, respectively.
HMQC Analysis showed that these C-atoms were attached to H-atoms resonating at
d(H) 4.15 and 5.24, respectively. These could readily be located by COSY coupling of
d(H) 4.15 to HC(10) at d(H) 2.06, and of d(H) 5.24 to HC(3) at d(H) 6.60,
supported by an HMBC interaction of d(C) 70.6 with HC(10). Since the strongly
deshielded methine at d(H) 5.24 was likely to correspond to the acetylated position, we
then placed the AcO group at C(2) and the OH function at C(1).
The configurations at C(1) and C(2) of 7 were determined by NOESY analysis,
which showed interactions between d(H) 4.15 (HC(1)) and 2.06 (HaC(10)), as well
as between d(H) 5.24 (HC(2)) and 2.94 (HbC(8)), in accord with the crystal
structures of 5 and 6 (Fig.), in which HC(8) is above the b-face of the A-ring.
Table 1. 13C-NMR Data of 5–8. Recorded at 100 MHz in CDCl3; d in ppm.
Position 5 7 8 Position 5 7 8
1 58.7 70.6 73.4 12 75.7 76.0 75.9
2 46.2 71.4 66.3 13 128.6 128.9 128.3
3 129.9 129.3 131.9 14 108.2 108.2 108.2
4 137.6 138.0 138.5 15 143.8 143.7 143.9
5 58.5 58.5 58.2 16 138.8 138.3 136.6
6 40.6 38.9 37.9 17 110.1 110.7 110.7
7 87.2 87.2 86.9 18 169.3 168.7 169.2
8 39.1 40.0 39.8 19 79.8 80.7 80.4
9 44.0 43.4 43.4 20 14.9 14.9 14.6
10 45.7 46.4 43.8 MeCO – 21.0 21.5
11 38.8 39.4 38.2 MeCO – 170.2 170.1
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Therefore, the configurations in 7 was deduced as 1b-OH and 2a-OAc, as predicted
from the reaction mechanism.
The high-resolution ESI mass spectrum of 8 showed the [MþNa]þ ion at m/z
439.1372, consistent with the molecular formula C22H24O8 . The 13C-NMR spectrum
(Table 1) was almost identical to that of 7, but with slightly varied chemical shifts for
C(1) and C(2) at d(C) 73.4 and 66.3, respectively. HMQC Analysis showed that these
signals correlated with those at d(H) 5.25 and 4.25, respectively. The former showed a
COSY correlation to d(H) 2.27 (HC(10)), and the latter correlated with d(H) 6.68
(HC(3)). This established that 8 had a 1-AcO and a 2-OH group. NOESY Data
further showed a correlation between d(H) 5.25 and 2.42 (HC(8)), establishing that
HC(1) was on the b-face, the substituent, thus, being in a-position. The H-atom at
C(2) showed no NOESY interactions, and, thus, the OH substituent was assigned to be
b-orientated, in agreement with the expected reaction mechanism.
For both reaction products 7 and 8, the rest of their 1H- and 13C-NMR signals were
virtually unchanged compared to those of 5, which confirmed that no other potential
reactions, such as opening of the bicyclic acetal group orMichael addition to the olefin
at C(3), had occurred under the conditions employed.
3. Biological Studies. Compounds 2–8 were tested for their binding affinity to the d-,
m-, and k-opioid receptors, using a competitive binding assay in C6m, C6d, and CHOk
cells, respectively, against the non-selective antagonist [3H]diprenorphine [12]. None of
these compounds showed greater than 50% inhibition of binding at 10 mm concen-
tration, and, thus, no significant binding to any of these receptors.
Conclusions. – The previous hypothesis [5] that splendidin may be a good k-opioid
ligand is not supported by our studies. The model originally proposed [5] assumed H-
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Table 2. 1H-NMR Data of 5–8. Recorded at 400 MHz in CDCl3; d in ppm, J in Hz.
Position 5 7 8
1 3.54 (m) 4.15 (dd, J¼5.4, 3.9) 5.25 (m)
2 3.54 (m) 5.24 (dd, J¼3.9) 4.25 (m)
3 7.01 (t, J¼2.0) 6.60 (d, J¼3.9) 6.68 (d, J¼3.8)
6 2.16 (dd, J¼14.1),
1.42 (br. d, J¼14.1)
2.26 (dd, J¼14.2, 3.9),
1.51 (d, J¼14.2)
2.29 (d, J¼13.4),
1.48 (br. d, J¼13.4)
7 4.48 (br. d, J3.7) 4.51 (d, J¼3.9) 4.54 (m)
8 2.65 (q, J¼7.0) 2.94 (q, J¼7.0) 2.42 (q, J¼7.2)
10 2.07 (br. s) 2.06 (d, J¼5.4) 2.27 (d, J¼4.8)
11 2.88 (dd, J¼7.8, 5.3),
1.97 (dd, J¼7.8, 5.3)
2.88 (dd, J¼7.9, 5.9),
1.80 (dd, J¼7.9, 5.9)
2.67 (dd, J¼7.7, 5.3),
1.84 (dd, J¼7.7, 5.3)
12 5.35 (t, J¼7.8) 5.28 (t, J¼7.9) 5.28 (t, J¼7.7)
14 6.30 (m) 6.30 (m) 6.28 (m)
15 7.40 (m) 7.39 (m) 7.38 (m)
16 7.37 (m) 7.35 (m) 7.35 (m)
17 5.26 (s) 5.26 (s) 5.18 (s)






20 1.36 (d, J¼7.0) 1.36 (d, J¼7.0) 1.30 (d, J¼7.2)
Ac – 2.10 (s) 2.12 (s)
bonding interactions between a tyrosine OH group and the acceptor C¼O groups at
positions 1 and 18 of salvinorin (1), and between a glutamine residue and the furan O-
atom of 1. The same group later revised their model in the light of point-mutation
studies to include hydrophobic interactions with the Me groups of the AcO and methyl
ester functions of 1 [13]. A recent independent modeling study [14] confirms the
importance of hydrophobic interactions in receptor binding by salvinorin A. Thus,
although the H-bond acceptor sites of splendidin (2) can be mapped onto those of
salvinorin A (1), the former lacks hydrophobic groups at the important positions 2 and
18.
Although salvifarin (5) and its semi-synthetic derivatives 7 and 8 were inactive as
well, this work demonstrates the usefulness of this multifunctional diterpenoidal system
in allowing selective chemical modification of the clerodane scaffold. As modeling
studies become more sophisticated, there will be a continuing need for natural and
semi-synthetic diterpenoids to explore the highly potent and selective k-opioid agonist
salvinorin (1) and the nature of its interactions with the receptor.
M. G. R. thanks the EPSRC National Mass Spectrometry Service Centre, University of Wales,
Swansea, for mass-spectrometric support.
Experimental Part
General. Hexane (reagent grade), AcOEt, CH2Cl2 (anal. grade), MeOH, MeCN (HPLC grade),
H2SO4, and NaHCO3 were supplied by Fisher. Vanillin and indium trifluoromethanesulfonate (triflate)
were obtained from Aldrich. Silica-gel 60 for column chromatography (CC) and precoated silica-gel
GF254 plates on Al backing for TLC were obtained fromMerck. Semi-prep. HPLC was carried out with a
Constametric-4100 constant-volume pump, a Jasco UV-1575 variable-wavelength UV detector (218 nm),
and a Phenomenex Synergi 4mMAX-RP 8A column (25010.0 mm) maintained at 408 in a SSI-505 LC
column oven, eluting at a flow rate of 5 ml/min. Fractions were collected manually. IR Spectra were
recorded on a Perkin-Elmer RX1 FT-IR instrument; in cm1. NMR Spectra were obtained on Jeol GX-
270 or Varian Mercury 400 spectrometers. Samples were dissolved in CDCl3, and chemical shifts d are
reported in ppm rel. to internal Me4Si. 2D-NMR (COSY, DEPT, HMQC, HMBC, NOESY) experiments
were performed using normal pulse sequences. Low-resolution EI-MS (70 eV) and pos.-ion CI-MS
(reagent ammonia) was carried out on aMicromass Quattro-II apparatus, and high-resolution (HR) MS
was carried out on a Finnigan MAT-900-XLT mass spectrometer, both at the EPSRC National Mass
Spectrometry Service Centre, University of Wales, Swansea. HR-ESI-MS was carried out on a Bruker
Daltonics MicroTOF instrument (pos. mode); all values in m/z.
X-Ray Crystal Structure1). A single crystal of salvifaricin (6) was analyzed at 150(2) Kusing graphite-
monochromated MoKa radiation on a Nonius Kappa-CCD diffractometer. Details of the data collection
and refinement are given in Table 3. The structure was solved with SHELXS-97, and refined by means of
full-matrix least squares in SHELXL-97 [15].
Plant Material. Salvia splendens cv. Blaze of Fire, and Salvia farinacea cv. Victoria were grown in
Bath, UK, from commercially available seeds. The plants were collected during the late flowering period,
and air-dried.
Extraction and Isolation of Diterpenoids from S. splendens. Compounds 2–4 were isolated from the
aerial parts of S. splendens by adaptation of reported methods [16]. Briefly, the powdered plant material
(450 g dry weight) was macerated at r.t. with acetone (3 ). The combined acetone extracts were
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1) The crystallographic data of 6 have been deposited with the Cambridge Crystallographic Data
Centre as supplementary publication number CCDC-616424. Copies of the data can be obtained,
free of charge, at http://www.ccdc.cam.ac.uk/data_request/cif.
evaporated to dryness at reduced pressure, and the resulting residue was re-extracted with AcOEt (3 ).
Evaporation of the solvent yielded a crude extract (5.6 g). A portion of this extract (2.5 g) was
fractionated by CC (50 g SiO2), eluting with a step gradient, starting with 5% AcOEt in hexane
(1500 ml), followed by 10% AcOEt in hexane (1000 ml), and then in 5% steps up to 40% AcOEt in
hexane (500 ml each). Fractions (ca. 45 ml) were collected and monitored by TLC and NMR
spectroscopy. The fractions obtained with 40%AcOEt in hexane were combined and further purified by
semi-prep. HPLC, eluting with 27% MeCN in H2O. The HPLC retention times (tR) were 70, 77, and
82 min for splendidin (2 ; 43 mg), salviarin (3 ; 33 mg), and splenolide B (4 ; 21 mg), resp.
Extraction and Isolation of Diterpenoids from S. farinacea. The powdered plant material (1500 g dry
weight) was extracted as described above to yield a crude AcOEt-soluble extract (28 g). A portion of this
extract (20 g) was separated by CC (100 g SiO2), eluting with 5% AcOEt in hexane (1500 ml), followed
by steps of 15, 30, 40, 45, 50, 70, 80, and 90%AcOEt in hexane (1000 ml each). Fractions (ca. 45 ml) were
collected and monitored by TLC and NMR spectroscopy. On solvent evaporation, crystals separated
from the fractions containing 45 and 50% AcOEt. These were collected and recrystallized from CH2Cl2/
MeCN to yield salvifarin (5) (0.17 g) in the form of needle-shaped crystals. The mother liquors and the
more-polar fractions were combined and concentrated, and the residue (3.4 g) was fractionated further
by CC (100 g SiO2), eluting with 1% MeOH in CH2Cl2 (9000 ml), followed by 2 and 3% MeOH in
CH2Cl2 (1000 ml each). Fractions (ca. 60 ml) were collected and monitored by TLC and NMR
spectroscopy. The fractions eluting between 3000 and 6000 ml of 1%MeOH in CH2Cl2 yielded a further
crop of crystalline 5 (0.13 g after recrystallization). The fractions eluting between 6000 ml of 1%MeOH
and of 400 ml of 3% MeOH in CH2Cl2 yielded crystalline salvifaricin (6 ; 12 mg after recrystallization
from CH2Cl2/MeCN). Additional 6 was obtained by semiprep. HPLC of the mother liquors, eluting with
33% MeCN in H2O (tR 33 min).
Derivatization of Salvifarin (5). AcOH (50 mg, 0.8 mmol) and indium triflate (120 mg, 0.2 mmol)
were added to a soln. of 5 (135 mg, 0.4 mmol) in anh. CH2Cl2 (10 ml) at r.t. The mixture was stirred at
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Crystal size [mm] 0.500.500.50
q Range [8] 3.67–30.05
Miller indices 15h15; 15k15; 17 l17
Reflections collected 30,819
Independent reflections; R(int) 4,656; 0.0414
Reflections observed (> 2s) 4,482
Data/restraints/parameters 4656/0/228
Goodness-of-fit on F 2 1.045
Final R1, wR2 [I>2s(I)] 0.0306, 0.0804
Final R1, wR2 (all data) 0.0321, 0.0818
Absolute structure parameter 0.0(5)
Max. and min. residual density [e/Q3] 0.253, 0.188
reflux for 90 min (TLC control). The mixture was then washed with sat. aq. NaHCO3 soln. (320 ml),
and the combined aq. layer was re-extracted with CH2Cl2. The org. layers were combined, dried, and
concentrated under reduced pressure to yield a crude product (165 mg), which was separated by CC
(SiO2), eluting with 35% AcOEt in hexane, to yield 7 (50 mg) and 8 (20 mg).
(1S,2S,7R,10a,12R,17R)-2-Acetoxy-7,17 : 12,17 : 15,16-triepoxy-1-hydroxycleroda-3,13(16),14-trien-
18,19-olid (7). Colorless, amorphous solid. IR (KBr): 2921, 1741, 1728, 1374, 1247, 1201, 1059, 1026. 1H-
and 13C-NMR: see Tables 2 and 1, resp. EI-MS: 416.2 (8,Mþ ), 356.1 (14), 275.1 (20), 95.0 (55), 94.0 (50),
81.0 (50), 69.1 (24), 55.0 (36), 43 (100). CI-MS (NH3): 434.2 (100, [MþNH4]þ ). HR-CI-MS: 434.1816
([MþNH4]þ , C22H28NOþ8 , calc. 434.1815).
(1R,2R,7R,10a,12R,17R)-1-Acetoxy-7,17 : 12,17 : 15,16-triepoxy-2-hydroxycleroda-3,13(16),14-trien-
18,19-olid (8). Colorless, amorphous solid. IR (KBr): 2919, 1746, 1744, 1376, 1232, 1053, 1016. 1H- and
13C-NMR: see Tables 2 and 1, resp. EI-MS: 416.2 (8,Mþ ), 368.1 (5), 356.1 (5), 340.1 (6), 105.1 (71), 95.0
(56), 81.1 (50), 69.1 (46), 55.1 (56), 43 (100). HR-ESI-MS: 439.1372 ([MþNa]þ , C22H24NaOþ8 ; calc.
439.1369).
Biological Studies. Compounds 2–8 were examined for their receptor-binding affinities in a
competitive binding assay against the non-selective antagonist [3H]diprenorphine in membrane
preparations derived from C6m, C6d, and CHOk cells.
Briefly, C6 glioma cells, stably transfected with the m- or d-opioid receptors (C6m and C6d) [17], and
Chinese hamster ovary cells expressing the human k-opioid receptor (CHOk cells) [18], were cultured
under a 5% CO2 atmosphere in Dulbecco=s modified Eagle medium (for the C6 cells), or in Dulbecco=s
modified Eagle medium/nutrient mix F-12 (for Chinese hamster ovary cells), supplemented with 10%
fetal calf serum (FCS). For subculture, one flask from each passage was grown in the presence of
geneticin. The cells used for the experiments were grown in the absence of geneticin, with no significant
reduction in receptor number. Once the cells had reached confluency, they were harvested in 20 mm
HEPES-buffered saline (pH 7.4), containing 1 mm EDTA, dispersed by agitation, and collected by
centrifugation at 1,600 r.p.m. The cell pellet was suspended in 50 mm Tris ·HCl buffer (pH 7.4), and
homogenized with a Tissue-Tearor (Biospec Products, Bartlesville, OK, USA). The resultant
homogenate was centrifuged for 15 min at 18,000 r.p.m. at a temp. of 48. The pellet was collected, re-
suspended in 50 mm Tris ·HCl buffer (pH 7.4), separated into 0.5 ml aliquots (0.75–1.0 mg protein), and
frozen at 808. Protein concentrations were determined by the method ofLowry et al. [19], using bovine
serum albumin (BSA) as standard.
For ligand binding, the cell membranes (30–60 mg protein) were incubated at 258 in 50 mm Tris ·HCl
buffer (pH 7.4) for 1 h with 0.2 nm [3H]diprenorphine (final volume of 1 ml). Non-specific binding was
defined with 10 mm naloxone. Reactions were terminated by filtration through glass-fiber filters
(Schleicher & Schuell, Keene, NH, USA), and mounted in a Bandel 24-well harvester. The filters were
washed three times with ice-cold Tris ·HCl (pH 7.4), and the radioactivity retained was determined by
scintillation counting after the addition of Ultima Gold liquid-scintillation fluid (3 ml).
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